tag:blogger.com,1999:blog-36634196.post704255139319014642..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: Genentech Wanted Roche To Pay How Much?Chris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-36634196.post-43017648852404192172009-02-11T10:48:00.000-05:002009-02-11T10:48:00.000-05:00EdIt seems to me that Roche are doing the usual "b...Ed<BR/><BR/>It seems to me that Roche are doing the usual "buyer" thing of suggesting that Genentech are being over optimistic about their financial future, and Genentech are standing firm behind their conviction that they are worth well over $100 per share. If oncology pricing moves the way most observers believe it will (i.e. sharply downwards) over the next 10 years, it rather suggests that Roche may be right. Add to that the massive competition coming in oncology over the same time frame (part of the reason prices will fall), and you have a tricky position within which Genentech say they are going to continue to over perform.<BR/><BR/>That, of course doesn't make it more likely that Genentech share holders will sell, but those projections have got to be worth a very close look.Anonymousnoreply@blogger.com